Posted by Michael Wonder on 19 Oct 2020
Janssen receives CHMP positive opinion for expanded use of Tremfya (guselkumab) in the treatment of active psoriatic arthritis in the European Union
16 October 2020 - If approved, guselkumab will be the first selective interleukin 23 p19 sub-unit inhibitor licensed for both the treatment of psoriatic arthritis and moderate to severe plaque psoriasis.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the CHMP of the EMA adopted a positive opinion recommending the expanded use of Tremfya (guselkumab) for the treatment of adult patients with active psoriatic arthritis in the European Union (EU).
Guselkumab is currently approved in the EU for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
